Get notified when INM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states that winding down its only revenue-generating segment creates substantial uncertainty about its ability to continue as a going concern, and its auditors have issued going-concern warnings for two consecutive fiscal years.
- Material Weakness (new) — The company acknowledges exposure from failure to fully remediate any material weakness in internal controls, a significant governance and financial reporting risk.
- Dilution (new) — New investors face immediate dilution of $(1.20) per share, and the company has a substantial overhang of outstanding options and warrants, including 1,150,363 pre-funded warrants with an exercise price of $0.0001.
InMed Pharmaceuticals files for up to $1.2M at-the-market offering at $0.67/share amid going-concern warning
Filed April 3, 2026 · ~2 min read
Key Changes
-
high
InMed is offering up to 1,811,416 common shares at $0.67 per share in an at-the-market offering, with gross proceeds of up to $1,213,648 and net proceeds to the company of $1,119,279.
The Offering verify on EDGAR → -
high
The company is winding down BayMedica, its only revenue-generating segment, with completion targeted before June 30, 2026, creating substantial uncertainty about its ability to continue as a going concern.
Risk Factors verify on EDGAR → -
high
InMed received a Nasdaq delisting notice on March 27, 2026, because its stock price closed below $1.00 for 30 consecutive trading days; it has 180 days to regain compliance.
Risk Factors verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade INM commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify